Navigation Links
ViewRay Demonstrates Potential Therapy Applications for MRI-Guided Radiation at ASTRO 2011
Date:9/29/2011

CLEVELAND, Sept. 29, 2011 /PRNewswire/ -- ViewRay™, Inc., a privately held medical device company, will present potential applications for MRI-guided radiotherapy at the annual meeting of the American Society for Radiation Oncology (ASTRO) October 2 – 4 in Miami Beach, Florida, with software demonstrations in booth #865. The company's new research radiation therapy system is being developed to feature a patented combination of radiotherapy delivery and simultaneous magnetic resonance imaging (MRI). The system is being designed to let radiation oncologists see what they're treating, while they're treating.

Visitors to ViewRay's ASTRO booth can view software demonstrations and learn about the key capabilities being designed into the system. In addition to quality pretreatment imaging and advanced treatment delivery, the ViewRay system is being developed to enable:

  • On-table dose prediction — fast dose prediction using volumetric image data captured just prior to treatment.
  • Soft-tissue targeting — continuous, MRI-guided tracking of soft tissues and automatic beam control for real-time adaptation to motion.
  • Adaptive optimization — fast, convenient reoptimization for effective online and offline plan adaptation.
  • Review and assessment — software tools that help physicians better understand and manage the progress of treatment.

ViewRay holds the exclusive worldwide license for its combination of MRI and radiation therapy technologies. Earlier this year, landmark patents were issued for ViewRay's core technology in both the United States and Europe. ViewRay's treatment planning and delivery software recently received 510(k) premarket notification clearance from the U.S. FDA, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review. The ViewRay system is currently available only as a non–human use research system.

"With the 510(k) clearance of our software, the issuance of patents on our technology, and the addition of several new research partners, we've reached major milestones this year," said ViewRay President and CEO Gregory M. Ayers, MD, PhD. "We're looking forward to sharing our progress with the ASTRO community." ViewRay research partners now include the University of California, Los Angeles (UCLA) Health System – Jonsson Comprehensive Cancer Center, the University of Wisconsin Carbone Cancer Center, and the Siteman Cancer Center at Barnes Jewish Hospital and Washington University School of Medicine, where the first ViewRay research system is currently being installed.

About ViewRay

ViewRay, Inc., of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system is being designed to provide continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.

ViewRay is a trademark of ViewRay, Inc.


'/>"/>
SOURCE ViewRay, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViewRay Wins NorTech Innovation Award
2. Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System
3. ViewRay Secures Series C Financing
4. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
5. University of Wisconsin Carbone Cancer Center to Acquire ViewRay Radiation Therapy System
6. Landmark Patents Issued for ViewRay Technology
7. UCLA Health System - Jonsson Comprehensive Cancer Center to Acquire ViewRay Radiation Therapy Research System
8. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
9. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
10. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
11. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... N.C. , Feb. 12, 2016  Clinical Affairs leaders at ... presence in emerging areas of the world. While some companies have ... lag in their clinical activity in countries such as ... China and India ... market products in those countries. --> China ...
(Date:2/12/2016)... 2016   National Community Pharmacists Association (NCPA) ... the following statement today in response to the detailed ... Centers for Medicare & Medicaid Services (CMS) and conducted ... and others: patient advocacy organizations and ... the full CMS analysis. Our initial reaction is that ...
(Date:2/12/2016)... 12, 2016  This month,s issue of the ... takes an in-depth look at various causes and consequences associated ... drug spending, which has generated significant public outrage and ... Laura E. Happe , PharmD, MPH. --> ... PharmD, MPH. --> In 2014 prescription drug ...
Breaking Medicine Technology:
(Date:2/13/2016)... ... February 13, 2016 , ... Good ... the first in the area to offer AngioPlex™ Optical Coherence Tomography (OCT) Angiography, ... such as macular degeneration, diabetic retinopathy, and other vascular conditions. , In just ...
(Date:2/13/2016)... ... , ... Hidden Cypress in Sun City is the place to be on March 3rd to ... Weniger will be hosting this educational seminar from 5:30 p.m. – 7:00 p.m. Exciting ... pricing on offers. In addition, prizes will be given away and light refreshments will be ...
(Date:2/13/2016)... California (PRWEB) , ... February 13, 2016 , ... Valentine’s ... landing a date for the big day. A great outfit, flawless hair, and a ... they might as well resign themselves to a night at home with Rover. (Actually, ...
(Date:2/13/2016)... Washington, D.C. (PRWEB) , ... February 13, 2016 ... ... joined with Faces and Voices of Recovery, the leading national organization representing the ... paper urging candidates for public office to include Family Recovery in policies addressing ...
(Date:2/13/2016)... ... February 13, 2016 , ... Many individuals looking to lead a ... multitude of reasons. IsoPasta by Isolator Fitness has delved into this niche allowing ... without the high-carb repercussions. IsoPasta has 30 grams of protein and only 7 ...
Breaking Medicine News(10 mins):